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THE WOMEN’S HEALTH INITIA-tive (WHI) focuses on defin-ing the risks and benefits ofstrategies that could poten-
tially reduce the incidence of heart dis-
ease, breast and colorectal cancer, and
fractures in postmenopausal women.
Between 1993 and 1998, the WHI en-
rolled 161809 postmenopausal women
in the age range of 50 to 79 years into
a set of clinical trials (trials of low-fat
dietary pattern, calcium and vitamin D
supplementation, and 2 trials of post-
menopausal hormone use) and an ob-
servational study at 40 clinical centers
in the United States.1 This article re-
ports principal results for the trial of
combined estrogen and progestin in
women with a uterus. The trial was
stopped early based on health risks that
exceeded health benefits over an aver-
age follow-up of 5.2 years. A parallel
trial of estrogen alone in women who
have had a hysterectomy is being con-
tinued, and the planned end of this trial
is March 2005, by which time the av-
erage follow-up will be about 8.5 years.
The WHI clinical trials were de-
signed in 1991-1992 using the accu-
mulated evidence at that time. The pri-
mary outcome for the trial of estrogen
plus progestin was designated as coro-
nary heart disease (CHD). Potential car-
dioprotection was based on generally
Author Information and Financial Disclosures appear at the end of this article.
Context Despite decades of accumulated observational evidence, the balance of risks
and benefits for hormone use in healthy postmenopausal women remains uncertain.
Objective To assess the major health benefits and risks of the most commonly used
combined hormone preparation in the United States.
Design Estrogen plus progestin component of the Women’s Health Initiative, a ran-
domized controlled primary prevention trial (planned duration, 8.5 years) in which 16608
postmenopausal women aged 50-79 years with an intact uterus at baseline were re-
cruited by 40 US clinical centers in 1993-1998.
Interventions Participants received conjugated equine estrogens, 0.625 mg/d, plus
medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n=8506) or placebo (n=8102).
Main Outcomes Measures The primary outcome was coronary heart disease (CHD)
(nonfatal myocardial infarction and CHD death), with invasive breast cancer as the
primary adverse outcome. A global index summarizing the balance of risks and ben-
efits included the 2 primary outcomes plus stroke, pulmonary embolism (PE), endo-
metrial cancer, colorectal cancer, hip fracture, and death due to other causes.
Results On May 31, 2002, after a mean of 5.2 years of follow-up, the data and safety
monitoring board recommended stopping the trial of estrogen plus progestin vs placebo
because the test statistic for invasive breast cancer exceeded the stopping boundary for
this adverse effect and the global index statistic supported risks exceeding benefits. This
report includes data on the major clinical outcomes through April 30, 2002. Estimated
hazard ratios (HRs) (nominal 95% confidence intervals [CIs]) were as follows: CHD, 1.29
(1.02-1.63) with 286 cases; breast cancer, 1.26 (1.00-1.59) with 290 cases; stroke, 1.41
(1.07-1.85) with 212 cases; PE, 2.13 (1.39-3.25) with 101 cases; colorectal cancer, 0.63
(0.43-0.92) with 112 cases; endometrial cancer, 0.83 (0.47-1.47) with 47 cases; hip frac-
ture, 0.66 (0.45-0.98) with 106 cases; and death due to other causes, 0.92 (0.74-1.14)
with 331 cases. Corresponding HRs (nominal 95% CIs) for composite outcomes were
1.22 (1.09-1.36) for total cardiovascular disease (arterial and venous disease), 1.03 (0.90-
1.17) for total cancer, 0.76 (0.69-0.85) for combined fractures, 0.98 (0.82-1.18) for total
mortality, and 1.15 (1.03-1.28) for the global index. Absolute excess risks per 10000 person-
years attributable to estrogen plus progestin were 7 more CHD events, 8 more strokes, 8
more PEs, and 8 more invasive breast cancers, while absolute risk reductions per 10000
person-years were 6 fewer colorectal cancers and 5 fewer hip fractures. The absolute ex-
cess risk of events included in the global index was 19 per 10000 person-years.
Conclusions Overall health risks exceeded benefits from use of combined estrogen
plus progestin for an average 5.2-year follow-up among healthy postmenopausal US
women. All-cause mortality was not affected during the trial. The risk-benefit profile
found in this trial is not consistent with the requirements for a viable intervention for
primary prevention of chronic diseases, and the results indicate that this regimen should
not be initiated or continued for primary prevention of CHD.
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For editorial comment see p 366.
©2002 American Medical Association. All rights reserved. (Reprinted) JAMA, July 17, 2002—Vol 288, No. 3 321
Downloaded From: https://jamanetwork.com/ by a University of California - San Diego User  on 05/16/2019
supportive data on lipid levels in inter-
mediate outcome clinical trials, trials in
nonhuman primates, and a large body
of observational studies suggesting a
40% to 50% reduction in risk among
users of either estrogen alone or, less
frequently, combined estrogen and pro-
gestin.2-5 Hip fracture was designated as
a secondary outcome, supported by ob-
servational data as well as clinical tri-
als showing benefit for bone mineral
density.6,7 Invasive breast cancer was
designated as a primary adverse out-
come based on observational data.3,8 Ad-
ditional clinical outcomes chosen as
secondary outcomes that may plausi-
bly be affected by hormone therapy in-
clude other cardiovascular diseases; en-
dometrial, colorectal, and other cancers;
and other fractures.3,6,9
The effect of hormones on overall
health was an important consider-
ation in the design and conduct of the
WHI clinical trial. In an attempt to sum-
marize important aspects of health ben-
efits vs risks, a global index was de-
fined as the earliest occurrence of CHD,
invasive breast cancer, stroke, pulmo-
nary embolism (PE), endometrial can-
cer, colorectal cancer, hip fracture, or
death due to other causes. Compared
with total mortality, which may be too
insensitive, this index assigns addi-
tional weight to the 7 listed diseases.
Procedures for monitoring the trial in-
volved semiannual comparisons of the
estrogen plus progestin and placebo
groups with respect to each of the el-
ements of the global index and to the
overall global index.
This report pertains primarily to
estrogen plus progestin use among
healthy postmenopausal women, since
only 7.7% of participating women re-
ported having had prior cardiovascu-
lar disease. During the course of the
WHI trial, the Heart and Estrogen/
progestin Replacement Study (HERS)
reported its principal results.10 HERS
was another blinded, randomized con-
trolled trial comparing the same regi-
men of estrogen plus progestin with pla-
cebo among women with a uterus;
however, in HERS, all 2763 participat-
ing women had documented CHD prior
to randomization. The HERS findings
of no overall effect on CHD but an ap-
parent increased risk in the first year
after randomization seemed surpris-
ing given preceding observational stud-
ies of hormone use in women with
CHD.3 Subsequent to HERS, some in-
vestigators reanalyzed their observa-
tional study data and were able to de-
tect an early elevation in CHD risk
among women with prior CHD11-13 but
not in ostensibly healthy women,14
prompting speculation that any early
adverse effect of hormones on CHD in-
cidence was confined to women who
have experienced prior CHD events.
The WHI is the first randomized trial
to directly address whether estrogen
plus progestin has a favorable or unfa-
vorable effect on CHD incidence and
on overall risks and benefits in pre-
dominantly healthy women.
METHODS
Study Population
Detailed eligibility criteria and recruit-
ment methods have been published.1
Briefly, most women were recruited by
population-based direct mailing cam-
paigns to age-eligible women, in con-
junction with media awareness pro-
grams. Eligibility was defined as age 50
to 79 years at initial screening, post-
menopausal, likelihood of residence in
the area for 3 years, and provision of writ-
ten informed consent. A woman was
considered postmenopausal if she had
experienced no vaginal bleeding for 6
months (12 months for 50- to 54-year-
olds), had had a hysterectomy, or had
ever used postmenopausal hormones.
Major exclusions were related to com-
peting risks (any medical condition likely
to be associated with a predicted sur-
vival of3 years), safety (eg, prior breast
cancer, other prior cancer within the last
10 years except nonmelanoma skin can-
cer, low hematocrit or platelet counts),
and adherence and retention concerns
(eg, alcoholism, dementia).
A 3-month washout period was re-
quired before baseline evaluation of
women using postmenopausal hor-
mones at initial screening. Women with
an intact uterus at initial screening were
eligible for the trial of combined post-
menopausal hormones, while women
with a prior hysterectomy were eli-
gible for the trial of unopposed estro-
gen. This report is limited to the 16608
women with an intact uterus at base-
line who were enrolled in the trial com-
ponent of estrogen plus progestin vs
placebo. The protocol and consent
forms were approved by the institu-
tional review boards for all participat-
ing institutions (see Acknowledgment).
Study Regimens, Randomization,
and Blinding
Combined estrogen and progestin was
provided in 1 daily tablet containing
conjugated equine estrogen (CEE),
0.625 mg, and medroxyprogesterone
acetate (MPA), 2.5 mg (Prempro,
Wyeth Ayerst, Philadelphia, Pa). A
matching placebo was provided to the
control group. Eligible women were
randomly assigned to receive estrogen
plus progestin or placebo after eligibil-
ity was established and baseline assess-
ments made (FIGURE 1). The random-
ization procedure was developed at the
WHI Clinical Coordinating Center and
implemented locally through a distrib-
uted study database, using a random-
ized permuted block algorithm, strati-
fied by clinical center site and age
group. All study medication bottles had
a unique bottle number and bar code
to allow for blinded dispensing.
Figure 1. Profile of the Estrogen Plus
Progestin Component of
the Women’s Health Initiative
8506 Assigned to
Receive Estrogen
+ Progestin
8102 Assigned to
Receive Placebo
18 845 Provided Consent and
Reported No Hysterectomy
373 092 Women Initiated Screening
16 608 Randomized
Status on April 30, 2002
7968 Alive and Outcomes
Data Submitted in
Last 18 mo
307 Unknown Vital 
Status
231 Deceased
Status on April 30, 2002
7608 Alive and Outcomes
Data Submitted in
Last 18 mo
276 Unknown Vital 
Status
218 Deceased
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Initially, the design allowed women
with a uterus to be randomized to re-
ceive unopposed estrogen, estrogen
plus progestin, or placebo. After the re-
lease of the Postmenopausal Estrogen/
Progestin Intervention (PEPI) trial
results15 indicating that long-term ad-
herence to unopposed estrogen was not
feasible in women with a uterus, the
WHI protocol was changed to random-
ize women with a uterus to only estro-
gen plus progestin or placebo in equal
proportions. The 331 women previ-
ously randomized to unopposed estro-
gen were unblinded and reassigned to
estrogen plus progestin. These women
are included in the estrogen plus pro-
gestin group in this report, resulting in
8506 participants in the estrogen plus
progestin group vs 8102 in the pla-
cebo group. Analysis of the data ex-
cluding the women randomized be-
fore this protocol change did not affect
the results. Considerable effort was
made to maintain blinding of other par-
ticipants and clinic staff. When re-
quired for safety or symptom manage-
ment, an unblinding officer provided
the clinic gynecologist, who was not in-
volved with study outcomes activities,
with the treatment assignment.
Follow-up
Study participants were contacted by
telephone 6 weeks after randomiza-
tion to assess symptoms and reinforce
adherence. Follow-up for clinical events
occurred every 6 months, with annual
in-clinic visits required. At each semi-
annual contact, a standardized inter-
view collected information on desig-
nated symptoms and safety concerns,
and initial reports of outcome events
were obtained using a self-adminis-
tered questionnaire. Adherence to study
interventions was assessed by weigh-
ing of returned bottles. The study pro-
tocol required annual mammograms
and clinical breast examinations; study
medications were withheld if safety pro-
cedures were not performed, but these
participants continued to be followed
up. Electrocardiograms were col-
lected at baseline and at follow-up years
3 and 6.
Data Collection, Management,
and Quality Assurance
All data were collected on standard-
ized study forms by certified staff ac-
cording to documented study proce-
dures. Study data were entered into a
local clinical center database devel-
oped and maintained by the Clinical
Coordinating Center and provided to
each site in the form of a local area net-
work connected to the Clinical Coor-
dinating Center through a wide area
network. Data quality was ensured
through standard data entry mecha-
nisms, routine reporting and database
checks, random chart audits, and rou-
tine site visits.
Maintenance/Discontinuation
of Study Medications
During the trial, some flexibility of the
dosages of both estrogen and proges-
tin was allowed to manage symptoms
such as breast tenderness and vaginal
bleeding. Vaginal bleeding was man-
aged according to an algorithm that ac-
counted for the time since randomiza-
tion, severity of the bleeding, treatment
assignment, and endometrial histol-
ogy. Women who had a hysterectomy
after randomization for indications
other than cancer were switched to un-
opposed estrogen or the correspond-
ing placebo without unblinding. These
women are included in the original ran-
domization group for analyses.
Permanent discontinuation of study
medication was required by protocol
for women who developed breast can-
cer, endometrial pathologic state (hy-
perplasia not responsive to treatment,
atypia, or cancer), deep vein thrombo-
sis (DVT) or PE, malignant mela-
noma, meningioma, triglyceride
level greater than 1000 mg/dL (11.3
mmol/L), or prescription of estrogen,
testosterone, or selective estrogen-
receptor modulators by their personal
physician. Medications were tempo-
rarily discontinued in participants
who had acute myocardial infarction
(MI), stroke, fracture, or major injury
involving hospitalization, surgery
involving use of anesthesia, any ill-
ness resulting in immobilization for
more than 1 week, or any other severe
illness in which hormone use is tem-
porarily inappropriate.
Outcome Ascertainment
Cardiovascular Disease. Coronary heart
disease was defined as acute MI requir-
ing overnight hospitalization, silent MI
determined from serial electrocardio-
grams (ECGs), or CHD death. The di-
agnosis of acute MI was established ac-
cording to an algorithm adapted from
standardized criteria16 that included car-
diac pain, cardiac enzyme and tropo-
nin levels, and ECG readings. The pri-
mary analyses included both definite and
probable MIs as defined by the algo-
rithm. Myocardial infarction occurring
during surgery and aborted MIs were in-
cluded. An aborted MI was defined as
chest pain and ECG evidence of acute
MI at presentation, an intervention (eg,
thrombolysis) followed by resolution of
ECG changes, and all cardiac enzyme
levels within normal ranges. Silent MI
was diagnosed by comparing baseline
and follow-up ECGs at 3 and 6 years af-
ter randomization. Coronary death was
defined as death consistent with CHD
as underlying cause plus 1 or more of
the following: preterminal hospitaliza-
tion with MI within 28 days of death,
previous angina or MI and no poten-
tially lethal noncoronary disease, death
resulting from a procedure related to
coronary artery disease, or death cer-
tificate consistent with CHD as the un-
derlying cause. Stroke diagnosis was
based on rapid onset of a neurologic defi-
cit lasting more than 24 hours, sup-
ported by imaging studies when avail-
able. Pulmonary embolism and DVT
required clinical symptoms supported
by relevant diagnostic studies.
Cancer. Breast, colorectal, endome-
trial, and other cancers were con-
firmed by pathological reports when
available. Current data indicate that at
least 98% of breast, colorectal, and en-
dometrial cancers and 92% of other can-
cers were documented with pathologi-
cal reports.
Fractures. Reports of hip, verte-
bral, and other osteoporotic fractures
(including all fractures except those of
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the ribs, chest/sternum, skull/face, fin-
gers, toes, and cervical vertebrae) were
routinely ascertained. All fracture out-
comes were verified by radiology re-
ports. Study radiographs were not ob-
tained to ascertain subclinical vertebral
fractures.
This report is based on outcomes
adjudicated by clinical center physi-
cian adjudicators, as used for trial-
monitoring purposes. Clinical center
physician adjudicators were centrally
trained and blinded to treatment as-
signment and participants’ symptoms.
Future communications will report re-
sults based on centrally adjudicated out-
comes and will include a broader range
of outcomes with more extensive ex-
planatory analyses. Since this report is
presented before the planned study
closeout, outcome information is still
being collected and adjudicated. Lo-
cal adjudication is complete for ap-
proximately 96% of the designated self-
reported events. To date, agreement
rates between local and central adju-
dication are: MI, 84%; revasculariza-
tion procedures, 97%; PE, 89%; DVT,
84%; stroke, 94%; invasive breast can-
cer, 98%; endometrial cancer, 96%; co-
lorectal cancer, 98%; hip fracture, 95%;
and specific cause of death, 82%. When
related cardiovascular conditions are
combined (eg, when unstable angina or
congestive heart failure is grouped with
MI), agreement rates exceed 94% for
cardiovascular disease and 90% for spe-
cific cause of death.
Statistical Analyses
All primary analyses use time-to-
event methods and are based on the in-
tention-to-treat principle. For a given
outcome, the time of event was de-
fined as the number of days from ran-
domization to the first postrandomiza-
tion diagnosis, as determined by the
local adjudicator. For silent MIs, the
date of the follow-up ECG applied. Par-
ticipants without a diagnosis were cen-
sored for that event at the time of last
follow-up contact. Primary outcome
comparisons are presented as hazard ra-
tios (HRs) and 95% confidence inter-
vals (CIs) from Cox proportional haz-
Table 1. Baseline Characteristics of the Women’s Health Initiative Estrogen Plus Progestin
Trial Participants (N = 16 608) by Randomization Assignment*
Characteristics
Estrogen + Progestin
(n = 8506)
Placebo
(n = 8102)
P
Value†
Age at screening, mean (SD), y 63.2 (7.1) 63.3 (7.1) .39
Age group at screening, y
50-59 2839 (33.4) 2683 (33.1)
60-69 3853 (45.3) 3657 (45.1) .80
70-79 1814 (21.3) 1762 (21.7)
Race/ethnicity
White 7140 (83.9) 6805 (84.0)
Black 549 (6.5) 575 (7.1)
Hispanic 472 (5.5) 416 (5.1)
.33
American Indian 26 (0.3) 30 (0.4)
Asian/Pacific Islander 194 (2.3) 169 (2.1)
Unknown 125 (1.5) 107 (1.3)
Hormone use
Never 6280 (73.9) 6024 (74.4)
Past 1674 (19.7) 1588 (19.6) .49
Current‡ 548 (6.4) 487 (6.0)
Duration of prior hormone use, y
5 1538 (69.1) 1467 (70.6)
5-10 426 (19.1) 357 (17.2) .25
10 262 (11.8) 253 (12.2)
Body mass index, mean (SD), kg/m2§ 28.5 (5.8) 28.5 (5.9) .66
Body mass index, kg/m2
25 2579 (30.4) 2479 (30.8)
25-29 2992 (35.3) 2834 (35.2) .89
30 2899 (34.2) 2737 (34.0)
Systolic BP, mean (SD), mm Hg 127.6 (17.6) 127.8 (17.5) .51
Diastolic BP, mean (SD), mm Hg 75.6 (9.1) 75.8 (9.1) .31
Smoking
Never 4178 (49.6) 3999 (50.0)
Past 3362 (39.9) 3157 (39.5) .85
Current 880 (10.5) 838 (10.5)
Parity
Never pregnant/no term pregnancy 856 (10.1) 832 (10.3)
.67
1 term pregnancy 7609 (89.9) 7233 (89.7)
Age at first birth, y
20 1122 (16.4) 1114 (17.4)
20-29 4985 (73.0) 4685 (73.0) .11
30 723 (10.6) 621 (9.7)
Treated for diabetes 374 (4.4) 360 (4.4) .88
Treated for hypertension or
BP 140/90 mm Hg
3039 (35.7) 2949 (36.4) .37
Elevated cholesterol levels requiring
medication
944 (12.5) 962 (12.9) .50
Statin use at baseline¶ 590 (6.9) 548 (6.8) .66
Aspirin use (80 mg/d) at baseline 1623 (19.1) 1631 (20.1) .09
History of myocardial infarction 139 (1.6) 157 (1.9) .14
History of angina 238 (2.8) 234 (2.9) .73
History of CABG/PTCA 95 (1.1) 120 (1.5) .04
History of stroke 61 (0.7) 77 (1.0) .10
History of DVT or PE 79 (0.9) 62 (0.8) .25
Female relative had breast cancer 1286 (16.0) 1175 (15.3) .28
Fracture at age 55 y 1031 (13.5) 1029 (13.6) .87
continued
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ards analyses,17 stratified by clinical
center, age, prior disease, and random-
ization status in the low-fat diet trial.
Two forms of CIs are presented,
nominal and adjusted. Nominal 95%
CIs describe the variability in the esti-
mates that would arise from a simple
trial for a single outcome. Although tra-
ditional, these CIs do not account for
the multiple statistical testing issues
(across time and across outcome cat-
egories) that occurred in this trial, so
the probability is greater than .05 that
at least 1 of these CIs will exclude unity
under an overall null hypothesis. The
adjusted 95% CIs presented herein use
group sequential methods to correct for
multiple analyses over time. A Bonfer-
roni correction for 7 outcomes as speci-
fied in the monitoring plan (described
herein) was applied to all clinical out-
comes other than CHD and breast can-
cer, the designated primary and pri-
mary adverse effect outcomes, and the
global index. The adjusted CIs are
closely related to the monitoring pro-
cedures and, as such, represent a con-
servative assessment of the evidence.
This report focuses primarily on re-
sults using the unadjusted statistics and
also relies on consistency across diag-
nostic categories, supportive data from
other studies, and biologic plausibil-
ity for interpretation of the findings.
Data and Safety Monitoring
Trial monitoring guidelines for early
stopping considerations were based on
O’Brien-Fleming boundaries18 using
asymmetric upper and lower bound-
aries: a 1-sided, .025-level upper bound-
ary for benefit and 1-sided, .05-level
lower boundaries for adverse effects.
The adverse-effect boundaries were fur-
ther adjusted with a Bonferroni correc-
tion for the 7 major outcomes other
than breast cancer that were specifi-
cally monitored (CHD, stroke, PE, co-
lorectal cancer, endometrial cancer, hip
fracture, and death due to other causes).
The global index of monitored out-
comes played a supportive role as a
summary measure of the overall bal-
ance of risks and benefits. Trial moni-
toring for early stopping consider-
ations was conducted semiannually by
an independent data and safety moni-
toring board (DSMB). Aspects of the
monitoring plan have been pub-
lished.19
RESULTS
Trial Monitoring
and Early Stopping
Formal monitoring began in the fall of
1997 with the expectation of final analy-
sis in 2005 after an average of approxi-
mately 8.5 years of follow-up. Late in
1999, with 5 interim analyses com-
pleted, the DSMB observed small but
consistent early adverse effects in car-
diovascular outcomes and in the global
index. None of the disease-specific
boundaries had been crossed. In the
spring of 2000 and again in the spring
of 2001, at the direction of the DSMB,
hormone trial participants were given
information indicating that increases in
MI, stroke, and PE/DVT had been ob-
served and that the trial continued be-
cause the balance of risks and benefits
remained uncertain.
In reviewing the data for the 10th in-
terim analyses on May 31, 2002, the
DSMB found that the adverse effects in
cardiovascular diseases persisted, al-
though these results were still within the
monitoring boundaries. However, the
design-specified weighted log-rank test
statistic for breast cancer (z=−3.19)
crossed the designated boundary
(z=−2.32) and the global index was sup-
portive of a finding of overall harm
(z=−1.62). Updated analyses includ-
ing 2 months of additional data, avail-
able by the time of the meeting, did not
appreciably change the overall results.
On the basis of these data, the DSMB
concluded that the evidence for breast
cancer harm, along with evidence for
some increase in CHD, stroke, and PE,
outweighed the evidence of benefit for
fractures and possible benefit for colon
cancer over the average 5.2-year fol-
low-up period. Therefore, the DSMB rec-
ommended early stopping of the estro-
gen plus progestin component of the
trial. Because the balance of risks and
benefits in the unopposed-estrogen com-
ponent remains uncertain, the DSMB
recommended continuation of that com-
ponent of the WHI. Individual trial par-
ticipants have been informed.
Baseline Characteristics
There were no substantive differences
between study groups at baseline; 8506
women were randomized into the es-
trogen plus progestin group and 8102
into the placebo group (TABLE 1). The
mean (SD) age was 63.3 (7.1) years.
Two thirds of the women who re-
ported prior or current hormone use
had taken combined hormones and one
third had used unopposed estrogen.
Table 1. Baseline Characteristics of the Women’s Health Initiative Estrogen Plus Progestin
Trial Participants (N = 16 608) by Randomization Assignment* (cont)
Characteristics
Estrogen + Progestin
(n = 8506)
Placebo
(n = 8102)
P
Value
Gail model 5-year risk of breast cancer, %
1 1290 (15.2) 1271 (15.7)
1-2 5384 (63.3) 5139 (63.4)
.64
2-5 1751 (20.6) 1621 (20.0)
5 81 (1.0) 71 (0.9)
No. of falls in last 12 mo
0 5168 (66.2) 5172 (67.5)
1 1643 (21.0) 1545 (20.2)
.18
2 651 (8.3) 645 (8.4)
3 349 (4.5) 303 (4.0)
*Data are presented as number (percentage) of patients unless otherwise noted. BP indicates blood pressure; CABG/
PTCA, coronary artery bypass graft/percutaneous transluminal coronary angioplasty; DVT, deep vein thrombosis;
and PE, pulmonary embolism.
†Based on 2 tests (categorical variables) or t tests (continuous variables).
‡Required a 3-month washout prior to randomization.
§Total number of participants with data available was 8470 for estrogen plus progestin and 8050 for placebo.
Among women who reported having a term pregnancy.
¶Statins are 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
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Prevalence of prior cardiovascular
disease was low and levels of cardio-
vascular risk factors were consistent
with a generally healthy population of
postmenopausal women. An assess-
ment of commonly studied breast
cancer risk factors, both individually
and combined using the Gail model,20
indicate that the cohort in general
was not at increased risk of breast
cancer.
Follow-up, Adherence,
and Unblinding
Vital status is known for 16025 ran-
domized participants (96.5%), includ-
ing 449 (2.7%) known to be deceased.
A total of 583 (3.5%) participants were
lost to follow-up or stopped providing
outcomes information for more than 18
months. The remaining 15576 (93.8%)
provided recent outcome information
(Figure 1).
At the time of this report, all women
had been enrolled for at least 3.5 years,
with an average follow-up of 5.2 years
and a maximum of 8.5 years. A sub-
stantial number of women had stopped
taking study drugs at some time (42%
of estrogen plus progestin and 38% of
placebo). Dropout rates over time
(FIGURE 2) exceeded design projec-
tions, particularly early on, but com-
pare favorably with community-based
adherence to postmenopausal hor-
mones.21 Some women in both groups
initiated hormone use through their
own clinician (6.2% in the estrogen plus
progestin group and 10.7% in the pla-
cebo group cumulatively by the sixth
Figure 2. Cumulative Dropout and Drop-in
Rates by Randomization Assignment and
Follow-up Duration
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Dropout refers to women who discontinued study
medication; drop-in, women who discontinued study
medication and received postmenopausal hormones
through their own clinician.
Table 2. Clinical Outcomes by Randomization Assignment*
Outcomes
No. of Patients (Annualized %)
Hazard Ratio Nominal 95% CI Adjusted 95% CI
Estrogen + Progestin
(n = 8506)
Placebo
(n = 8102)
Follow-up time, mean (SD), mo 62.2 (16.1) 61.2 (15.0) NA NA NA
Cardiovascular disease†
CHD 164 (0.37) 122 (0.30) 1.29 1.02-1.63 0.85-1.97
CHD death 33 (0.07) 26 (0.06) 1.18 0.70-1.97 0.47-2.98
Nonfatal MI 133 (0.30) 96 (0.23) 1.32 1.02-1.72 0.82-2.13
CABG/PTCA 183 (0.42) 171 (0.41) 1.04 0.84-1.28 0.71-1.51
Stroke 127 (0.29) 85 (0.21) 1.41 1.07-1.85 0.86-2.31
Fatal 16 (0.04) 13 (0.03) 1.20 0.58-2.50 0.32-4.49
Nonfatal 94 (0.21) 59 (0.14) 1.50 1.08-2.08 0.83-2.70
Venous thromboembolic disease 151 (0.34) 67 (0.16) 2.11 1.58-2.82 1.26-3.55
Deep vein thrombosis 115 (0.26) 52 (0.13) 2.07 1.49-2.87 1.14-3.74
Pulmonary embolism 70 (0.16) 31 (0.08) 2.13 1.39-3.25 0.99-4.56
Total cardiovascular disease 694 (1.57) 546 (1.32) 1.22 1.09-1.36 1.00-1.49
Cancer
Invasive breast 166 (0.38) 124 (0.30) 1.26 1.00-1.59 0.83-1.92
Endometrial 22 (0.05) 25 (0.06) 0.83 0.47-1.47 0.29-2.32
Colorectal 45 (0.10) 67 (0.16) 0.63 0.43-0.92 0.32-1.24
Total 502 (1.14) 458 (1.11) 1.03 0.90-1.17 0.86-1.22
Fractures
Hip 44 (0.10) 62 (0.15) 0.66 0.45-0.98 0.33-1.33
Vertebral 41 (0.09) 60 (0.15) 0.66 0.44-0.98 0.32-1.34
Other osteoporotic‡ 579 (1.31) 701 (1.70) 0.77 0.69-0.86 0.63-0.94
Total 650 (1.47) 788 (1.91) 0.76 0.69-0.85 0.63-0.92
Death
Due to other causes 165 (0.37) 166 (0.40) 0.92 0.74-1.14 0.62-1.35
Total 231 (0.52) 218 (0.53) 0.98 0.82-1.18 0.70-1.37
Global index§ 751 (1.70) 623 (1.51) 1.15 1.03-1.28 0.95-1.39
*CI indicates confidence interval; NA, not applicable; CHD, coronary heart disease; MI, myocardial infarction; CABG, coronary artery bypass grafting; and PTCA, percutaneous
transluminal coronary angioplasty.
†CHD includes acute MI requiring hospitalization, silent MI determined from serial electrocardiograms, and coronary death. There were 8 silent MIs. Total cardiovascular disease is
limited to events during hospitalization except venous thromboembolic disease reported after January 1, 2000.
‡Other osteoporotic fractures include all fractures other than chest/sternum, skull/face, fingers, toes, and cervical vertebrae, as well as hip and vertebral fractures reported sepa-
rately.
§The global index represents the first event for each participant from among the following types: CHD, stroke, pulmonary embolism, breast cancer, endometrial cancer, colorectal
cancer, hip fracture, and death due to other causes.
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year). These “drop-in” rates were also
greater than expected.
At the time of this report, clinic gyne-
cologists had been unblinded to treat-
ment assignment for 3444 women in the
estrogen plus progestin group and 548
women in the placebo group, primarily
to manage persistent vaginal bleeding.
During the trial, 248 women in the es-
trogen plus progestin group and 183 in
the placebo group had a hysterectomy.
Intermediate Cardiovascular
Disease End Points
Blood lipid levels, assessed in an 8.6%
subsample of fasting blood specimens
collected from women at baseline and
year 1, showed greater reductions in
low-density lipoprotein cholesterol
(−12.7%) and increases in high-
density lipoprotein cholesterol (7.3%)
and triglycerides (6.9%) with estrogen
plus progestin relative to placebo (data
not shown), consistent with HERS and
PEPI.10,22 Systolic blood pressure was,
on average, 1.0 mm Hg higher in women
taking estrogen plus progestin at 1 year,
rising to 1.5 mm Hg at 2 years and
beyond (data not shown). Diastolic
blood pressures did not differ.
Clinical Outcomes
Cardiovascular Disease. Overall CHD
rates were low (TABLE 2). The rate of
women experiencing CHD events was
increased by 29% for women taking es-
trogen plus progestin relative to pla-
cebo (37 vs 30 per 10 000 person-
years), reaching nominal statistical
significance (at the .05 level). Most of
the excess was in nonfatal MI. No sig-
nificant differences were observed in
CHD deaths or revascularization pro-
cedures (coronary artery bypass graft-
ing or percutaneous transluminal coro-
nary angioplasty). Stroke rates were also
higher in women receiving estrogen
plus progestin (41% increase; 29 vs 21
per 10000 person-years), with most of
the elevation occurring in nonfatal
events. Women in the estrogen plus
progestin group had 2-fold greater rates
of venous thromboembolism (VTE), as
well as DVT and PE individually, with
almost all associated CIs excluding 1.
Rates of VTE were 34 and 16 per 10000
person-years in the estrogen plus pro-
gestin and placebo groups, respec-
tively. Total cardiovascular disease,
including other events requiring hos-
pitalization, was increased by 22% in
the estrogen plus progestin group.
Cancer. The invasive breast cancer
rates in the placebo group were con-
sistent with design expectations. The
26% increase (38 vs 30 per 10000 per-
son-years) observed in the estrogen plus
progestin group almost reached nomi-
nal statistical significance and, as noted
herein, the weighted test statistic used
for monitoring was highly significant.
No significant difference was ob-
served for in situ breast cancers. Fol-
low-up rates for mammography were
comparable in the estrogen plus pro-
gestin and placebo groups. Colorectal
cancer rates were reduced by 37% (10
vs 16 per 10000 person-years), also
reaching nominal statistical signifi-
cance. Endometrial cancer incidence
was not affected, nor was lung cancer
incidence (54 vs 50; HR, 1.04; 95% CI,
0.71-1.53) or total cancer incidence.
Fractures. This cohort experienced
low hip fracture rates (10 per 10000
person-years in the estrogen plus pro-
gestin group vs 15 per 10000 person-
years in the placebo group). Estrogen
plus progestin reduced the observed hip
and clinical vertebral fracture rates by
one third compared with placebo, both
nominally significantly. The reduc-
tions in other osteoporotic fractures
(23%) and total fractures (24%) were
statistically significant (all associated
CIs exclude 1).
The global index showed a nomi-
nally significant 15% increase in the es-
trogen plus progestin group (170 vs 151
per 10000 person-years). There were no
differences in mortality or cause of death
between groups (TABLE 3).
Time Trends
The Kaplan Meier estimates of cumu-
lative hazards (FIGURE 3) for CHD in-
dicate that the difference between treat-
ment groups began to develop soon
after randomization. These curves pro-
vide little evidence of convergence
through 6 years of follow-up. The cu-
mulative hazards for stroke begin to di-
verge between 1 and 2 years after ran-
domization, and this difference persists
beyond the fifth year. For PE, the curves
separate soon after randomization and
show continuing adverse effects
throughout the observation period. For
breast cancer, the cumulative hazard
functions are comparable through the
first 4 years, at which point the curve
for estrogen plus progestin begins to rise
more rapidly than that for placebo.
Curves for colorectal cancer show ben-
efit beginning at 3 years, and curves for
hip fracture show increasing cumula-
tive benefit over time. The difference
in hazard rates for the global index
(FIGURE 4) suggests a gradual in-
crease in adverse effects compared with
benefits for estrogen plus progestin
through year 5, with a possible nar-
rowing of the difference by year 6; how-
ever, HR estimates tend to be unstable
beyond 6 years after randomization.
Total mortality rates are indistinguish-
able between estrogen plus progestin
and placebo.
Tests for linear trends with time since
randomization, based on a Cox pro-
portional hazards model with a time-
Table 3. Cause of Death by Randomization Assignment
No. (Annualized %)
Estrogen + Progestin (n = 8506) Placebo (n = 8102)
Total deaths 231 (0.52) 218 (0.53)
Adjudicated deaths 215 (0.49) 201 (0.49)
Cardiovascular 65 (0.15) 55 (0.13)
Breast cancer 3 (0.01) 2 (0.01)
Other cancer 104 (0.24) 86 (0.21)
Other known cause 34 (0.08) 41 (0.10)
Unknown cause 9 (0.02) 17 (0.04)
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dependent covariate, detected no trend
with time for CHD, stroke, colorectal
cancer, hip fracture, total mortality, or
the global index (TABLE 4). There was
some evidence for an increasing risk of
breast cancer over time with estrogen
plus progestin (z=2.56 compared with
a nominal z score for statistical signifi-
cance of 1.96) and a decreasing risk of
VTE with time (z=−2.45). These re-
sults must be viewed cautiously be-
cause the number of events in each
interval is modest, the data in later
years are still incomplete, and later year
comparisons are limited to women
still at risk of their first event for that
outcome.
Subgroup Analyses
Cardiovascular Disease. A small sub-
set of women (n=400; average follow-
up, 57.4 months) in WHI reported con-
ditions at baseline that would have
made them eligible for HERS, ie, prior
MI or revascularization procedures.
Among these women with established
coronary disease, the HR for subse-
quent CHD for estrogen plus proges-
tin relative to placebo was 1.28 (95%
CI, 0.64-2.56) with 19 vs 16 events. The
remaining women, those without prior
CHD, had an identical HR for CHD
(145 vs 106; HR, 1.28; 95% CI, 1.00-
1.65). Few women with a history of
VTE were enrolled, but these data sug-
gest a possibility that these women may
be at greater risk of future VTE events
when taking estrogen plus progestin (7
vs 1; HR, 4.90; 95% CI, 0.58-41.06)
than those without a history of VTE
(144 vs 66; HR, 2.06; 95% CI,
1.54-2.76). For stroke, prior history did
not confer additional risk (1 vs 5 in
women with prior stroke; HR, 0.46;
95% CI, 0.05-4.51; 126 vs 80 with no
prior stroke; HR, 1.47; 95% CI,
1.11-1.95). No noteworthy interac-
tions with age, race/ethnicity, body mass
index, prior hormone use, smoking sta-
tus, blood pressure, diabetes, aspirin
use, or statin use were found for the
effect of estrogen plus progestin on
CHD, stroke, or VTE.
Breast Cancer. Women reporting
prior postmenopausal hormone use
had higher HRs for breast cancer asso-
ciated with estrogen plus progestin
use than those who never used post-
menopausal hormones (among never
users, 114 vs 102; HR, 1.06; 95% CI,
0.81-1.38; for women with 5 years
of prior use, 32 vs 15; HR, 2.13; 95%
CI, 1.15-3.94; for women with 5-10
Figure 3. Kaplan-Meier Estimates of Cumulative Hazards for Selected Clinical Outcomes
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years of prior use, 11 vs 2; HR, 4.61;
95% CI, 1.01-21.02; and for women
with 10 years of prior use, 9 vs 5;
HR, 1.81; 95% CI, 0.60-5.43; test for
trend, z = 2.17). No interactions
between estrogen plus progestin and
age, race/ethnicity, family history,
parity, age at first birth, body mass
index, or Gail-model risk score were
observed for invasive breast cancer.
Further Analyses
Because a number of women stopped
study medications during follow-up,
several analyses were performed to ex-
amine the sensitivity of the principal HR
estimates to actual use of study medi-
cations. Analyses that censored a wom-
an’s event history 6 months after be-
coming nonadherent (using 80% of
or stopping study drugs) produced the
largest changes to estimated effect sizes.
This approach increased HRs to 1.51 for
CHD, to 1.49 for breast cancer, to 1.67
for stroke, and to 3.29 for VTE. Analy-
ses attributing events to actual hor-
mone use (“as treated,” allowing for a
6-month lag) produced more modest
changes to these estimates. Analyses ex-
cluding women randomized during the
period when the unopposed-estrogen
component was open to women with
a uterus and analyses stratifying by en-
rollment period did not substantially
Figure 4. Kaplan-Meier Estimates of Cumulative Hazards for Global Index and Death
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Table 4. Selected Clinical Outcomes by Follow-up Year and Randomization Assignment*
Outcomes
Year 1 Year 2 Year 3
E + P Placebo Ratio E + P Placebo Ratio E + P Placebo Ratio
No. of participant-years 8435 8050 8353 7980 8268 7888
Coronary heart disease 43 (0.51) 23 (0.29) 1.78 36 (0.43) 30 (0.38) 1.15 20 (0.24) 18 (0.23) 1.06
Stroke 17 (0.20) 17 (0.21) 0.95 27 (0.32) 15 (0.19) 1.72 30 (0.36) 16 (0.20) 1.79
Venous thromboembolism 49 (0.58) 13 (0.16) 3.60 26 (0.31) 11 (0.14) 2.26 21 (0.25) 12 (0.15) 1.67
Invasive breast cancer 11 (0.13) 17 (0.21) 0.62 26 (0.31) 30 (0.38) 0.83 28 (0.34) 23 (0.29) 1.16
Endometrial cancer 2 (0.02) 2 (0.02) 0.95 4 (0.05) 4 (0.05) 0.96 4 (0.05) 5 (0.06) 0.76
Colorectal cancer 10 (0.12) 15 (0.19) 0.64 11 (0.13) 9 (0.11) 1.17 6 (0.07) 8 (0.10) 0.72
Hip fracture 6 (0.07) 9 (0.11) 0.64 8 (0.10) 13 (0.16) 0.59 11 (0.13) 12 (0.15) 0.87
Total death 22 (0.26) 17 (0.21) 1.24 30 (0.36) 30 (0.38) 0.96 39 (0.47) 35 (0.44) 1.06
Global index 123 (1.46) 96 (1.19) 1.22 134 (1.60) 117 (1.47) 1.09 127 (1.54) 107 (1.36) 1.13
Outcomes
Year 4 Year 5 Year 6 and Later
z Score
for Trend†E + P Placebo Ratio E + P Placebo Ratio E + P Placebo Ratio
No. of participant-years 7926 7562 5964 5566 5129 4243
Coronary heart disease 25 (0.32) 24 (0.32) 0.99 23 (0.39) 9 (0.16) 2.38 17 (0.33) 18 (0.42) 0.78 −1.19
Stroke 25 (0.32) 14 (0.19) 1.70 16 (0.27) 8 (0.14) 1.87 12 (0.23) 15 (0.35) 0.66 −0.51
Venous thromboembolism 27 (0.34) 14 (0.19) 1.84 16 (0.27) 6 (0.11) 2.49 12 (0.23) 11 (0.26) 0.90 −2.45
Invasive breast cancer 40 (0.50) 22 (0.29) 1.73 34 (0.57) 12 (0.22) 2.64 27 (0.53) 20 (0.47) 1.12 2.56
Endometrial cancer 10 (0.13) 5 (0.07) 1.91 1 (0.02) 4 (0.07) 0.23 1 (0.02) 5 (0.12) 0.17 −1.58
Colorectal cancer 9 (0.11) 20 (0.26) 0.43 4 (0.07) 8 (0.14) 0.47 5 (0.10) 7 (0.16) 0.59 −0.81
Hip fracture 8 (0.10) 11 (0.15) 0.69 5 (0.08) 8 (0.14) 0.58 6 (0.12) 9 (0.21) 0.55 0.25
Total death 55 (0.69) 48 (0.63) 1.09 41 (0.69) 44 (0.79) 0.87 44 (0.86) 44 (1.04) 0.83 −0.79
Global index 155 (1.96) 127 (1.68) 1.16 112 (1.88) 77 (1.38) 1.36 100 (1.95) 99 (2.33) 0.84 −0.87
*E + P indicates estrogen plus progestin. All outcome data are number of patients (annualized percentage).
†Tests for trends are based on Cox proportional hazards models with time-dependent treatment effects. The z scores shown indicate trends across all years.
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affect the results. These analyses sug-
gest that the intention-to-treat esti-
mates of HRs may somewhat underes-
timate the effect sizes relative to what
would be observed with full adher-
ence to study medications.
COMMENT
The WHI provides evidence from a
large randomized trial that addresses the
important issue of whether most
women with an intact uterus in the de-
cades of life following menopause
should consider hormone therapy to
prevent chronic disease. The WHI en-
rolled a cohort of mostly healthy, eth-
nically diverse women, spanning a large
age range (50-79 years at baseline). It
is noteworthy that the increased risks
for cardiovascular disease and inva-
sive breast cancer were present across
racial/ethnic and age strata and were not
influenced by the antecedent risk sta-
tus or prior disease. Hence, the results
are likely to be generally applicable to
healthy women in this age range. At the
time the trial was stopped, the in-
creases in numbers of invasive breast
cancers, CHD, stroke, and PE made ap-
proximately equal contributions to
harm in the estrogen plus progestin
group compared with placebo, which
were not counterbalanced by the
smaller reductions in numbers of hip
fractures and colorectal cancers.
Cardiovascular Disease
Even though the trial was stopped early
for harm from breast cancer, a suffi-
cient number of CHD events had oc-
curred by 5.2 years of average fol-
low-up to suggest that continuation to
the planned end would have been un-
likely to yield a favorable result for the
primary outcome of CHD. Even if there
were a reversal of direction toward ben-
efit of a magnitude seen in the obser-
vational studies (ie, a risk reduction of
55%) during the remaining years, con-
ditional power analyses indicate that
less than 10% power remained for
showing potential benefit if the trial
continued.
The WHI finding that estrogen plus
progestin does not confer benefit for
preventing CHD among women with
a uterus concurs with HERS findings
among women with clinically appar-
ent CHD,10 with the Estrogen Replace-
ment for Atherosclerosis trial, in which
estrogen plus progestin did not in-
hibit progression,23 and with a trial in
women with unstable angina that did
not observe a reduction in ischemic
events.24 The finding of an increased
risk after initiation of treatment in WHI
is similar to HERS. In HERS, after 4.1
and 6.8 years of follow-up, hormone
therapy did not increase or decrease risk
of cardiovascular events in women with
CHD.25 The WHI extends these find-
ings to include a wider range of women,
including younger women and those
without clinically apparent CHD, and
indicates that the risk may persist for
some years.
Unlike CHD, the excess risk of stroke
in the estrogen plus progestin group
was not present in the first year but ap-
peared during the second year and per-
sisted through the fifth year. Prelimi-
nary analyses indicate that the modest
difference in blood pressure between
groups does not contribute much to an
explanation of the increase in strokes
(data not shown). The findings in WHI
for stroke are consistent with but some-
what more extreme than those of HERS,
which reported a nonsignificant 23% in-
crease in the treatment group.26 The re-
sults were also more extreme than those
of the Women’s Estrogen and Stroke
Trial of estradiol (without progestin) in
women with prior stroke, which found
no effect of estrogen on recurrent
strokes overall but some increase in the
first 6 months.27 Trials of the effect of
estradiol on carotid intima-media thick-
ness have yielded conflicting re-
sults.28,29 At least 1 observational study
has suggested that that use of estrogen
plus progestin is associated with higher
risk of stroke than estrogen alone.14 In
WHI, there was no indication that ex-
cess strokes due to estrogen plus pro-
gestin were more likely to occur in older
women, in women with prior stroke
history, by race/ethnicity, or in women
with high blood pressure at baseline.
Therefore, it appears that estrogen plus
progestin increases the risk of strokes
in apparently healthy women.
Venous thromboembolism is an ex-
pected complication of postmeno-
pausal hormones, and the pattern over
time in WHI is consistent with the find-
ings from HERS and several observa-
tional studies.30,31
Cancer
The WHI is the first randomized con-
trolled trial to confirm that combined es-
trogen plus progestin does increase the
risk of incident breast cancer and to
quantify the degree of risk. The WHI
could not address the risk of death due
to breast cancer because with the rela-
tively short follow-up time, few women
in the WHI have thus far died as a re-
sult of breast cancer (3 in the active treat-
ment group and 2 in the placebo group).
The risk of breast cancer emerged sev-
eral years after randomization. After an
average follow-up of about 5 years, the
adverse effect on breast cancer had
crossed the monitoring boundary. The
26% excess of breast cancer is consis-
tent with estimates from pooled epide-
miological data, which reported a 15%
increase for estrogen plus progestin use
for less than 5 years and a 53% increase
for use for more than 5 years.32 It is also
consistent with the (nonsignificant) 27%
increase found after 6.8 years of fol-
low-up in HERS.33
With more common use of estrogen
plus progestin, several epidemiological
studies have reported that estrogen plus
progestin appears to be associated with
greater risk of breast cancer than estro-
gen alone.34-37 In the PEPI trial, women
in the 3 estrogen plus progestin groups
had much greater increases in mammo-
graphic density (a predictor of breast
cancer) than women in the estrogen or
placebo groups.38 In WHI, the HR for es-
trogen plus progestin was not higher in
women with a family history or other
risk factors for breast cancer, except for
reported prior use of postmenopausal
hormones. This may suggest a cumula-
tive effect of years of exposure to post-
menopausal hormones.
Endometrial cancer rates were low
and were not increased by 5 years of es-
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trogen plus progestin exposure. Close
monitoring for bleeding and treat-
ment of hyperplasia may contribute to
the absence of increased risk of endo-
metrial cancer.
The reduction in colorectal cancer in
the hormone group is consistent with
observational studies, which have sug-
gested fairly consistently that users of
postmenopausal hormones may be at
lower risk of colorectal cancer.39 The
mechanisms by which hormone use
might reduce risk are unclear. Results
from other trials of postmenopausal
hormones will help resolve the effects
of hormones on colorectal cancer.40
Fractures
The reductions in clinical vertebral frac-
tures, other osteoporotic fractures, and
combined fractures supported the ben-
efit for hip fractures found in this trial.
These findings are consistent with the
observational data and limited data from
clinical trials41 and are also consistent
with the known ability of estrogen (with
or without progestin) to maintain bone
mineral density.42 The WHI is the first
trial with definitive data supporting the
ability of postmenopausal hormones to
prevent fractures at the hip, vertebrae,
and other sites.
Overall Risks and Benefits
At the end of the trial, the global in-
dex indicated that there were more
harmful than beneficial outcomes in the
estrogen plus progestin group vs the
placebo group. The monitored out-
comes included in the global index were
selected to represent diseases of seri-
ous import that estrogen plus proges-
tin treatment might affect, and do not
include a variety of other conditions and
measures that may be affected in un-
favorable or favorable ways (eg, gall-
bladder disease, diabetes, quality of
life, and cognitive function). The data
on these and other outcomes will be
the subject of future publications.
All-cause mortality was balanced
between the groups; however, longer
follow-up may be needed to assess
the impact of the incident diseases on
total mortality.
The absolute excess risk (or risk re-
duction) attributable to estrogen plus
progestin was low. Over 1 year, 10000
women taking estrogen plus progestin
compared with placebo might experi-
ence 7 more CHD events, 8 more
strokes, 8 more PEs, 8 more invasive
breast cancers, 6 fewer colorectal can-
cers, and 5 fewer hip fractures. Com-
bining all the monitored outcomes,
women taking estrogen plus progestin
might expect 19 more events per year
per 10000 women than women taking
placebo. Over a longer period, more typi-
cal of the duration of treatment that
would be needed to prevent chronic dis-
ease, the absolute numbers of excess out-
comes would increase proportionately.
During the 5.2 years of this trial, the
number of women experiencing a global
index event was about 100 more per
10000 women taking estrogen plus pro-
gestin than taking placebo. If the cur-
rent findings can be extrapolated to an
even longer treatment duration, the ab-
solute risks and benefits associated with
estrogen plus progestin for each of these
conditions could be substantial and on
a population basis could account for
tens of thousands of conditions caused,
or prevented, by hormone use.
Limitations
This trial tested only 1 drug regimen,
CEE, 0.625 mg/d, plus MPA, 2.5 mg/d,
in postmenopausal women with an in-
tact uterus. The results do not necessar-
ily apply to lower dosages of these drugs,
to other formulations of oral estrogens
and progestins, or to estrogens and pro-
gestins administered through the trans-
dermal route. It remains possible that
transdermal estradiol with progester-
one, which more closely mimics the nor-
mal physiology and metabolism of en-
dogenous sex hormones, may provide
a different risk-benefit profile. The WHI
findings for CHD and VTE are sup-
ported by findings from HERS, but there
is no other evidence from clinical trials
for breast cancer and colorectal cancer,
and only limited data from trials con-
cerning fractures.
Importantly, this trial could not dis-
tinguish the effects of estrogen from
those of progestin. The effects of pro-
gestin may be important for breast can-
cer and atherosclerotic diseases, in-
cluding CHD and stroke. Per protocol,
in a separate and adequately powered
trial, WHI is testing the hypothesis of
whether oral estrogen will prevent CHD
in 10739 women who have had a hys-
terectomy. The monitoring of this trial
is similar to that for the trial of estro-
gen plus progestin. At an average fol-
low-up of 5.2 years, the DSMB has rec-
ommended that this trial continue
because the balance of overall risks and
benefits remains uncertain. These re-
sults are expected to be available in
2005, at the planned termination.
The relatively high rates of discon-
tinuation in the active treatment arm
(42%) and crossover to active treat-
ment in the placebo arm (10.7%) are a
limitation of the study; however, the lack
of adherence would tend to decrease the
observed treatment effects. Thus, the re-
sults presented here may underesti-
mate the magnitude of both adverse ef-
fects on cardiovascular disease and breast
cancer and the beneficial effects on frac-
tures and colorectal cancer among
women who adhere to treatment.
The fact that the trial was stopped
early decreases the precision of esti-
mates of long-term treatment effects. A
longer intervention period might have
shown more pronounced benefit for
fractures and might have yielded a more
precise test of the hypothesis that treat-
ment reduces colorectal cancer. None-
theless, it appears unlikely that benefit
for CHD would have emerged by con-
tinuing the trial to its planned termina-
tion. The trial results indicate that treat-
ment for up to 5.2 years is not beneficial
overall and that there is early harm for
CHD, continuing harm for stroke and
VTE, and increasing harm for breast can-
cer with increasing duration of treat-
ment. This risk-benefit profile is not con-
sistent with the requirements for a viable
intervention for the primary preven-
tion of chronic diseases.
Implications
The WHI trial results provide the first
definitive data on which to base treat-
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ment recommendations for healthy post-
menopausal women with an intact
uterus. This trial did not address the
short-term risks and benefits of hor-
mones given for the treatment of meno-
pausal symptoms. On the basis of HERS
and other secondary prevention trials,
the American Heart Association recom-
mended against initiating postmeno-
pausal hormones for the secondary pre-
vention of cardiovascular disease.43 The
American Heart Association made no
firm recommendation for primary pre-
vention while awaiting the results from
randomized clinical trials such as WHI,
and stated that continuation of the treat-
ment should be considered on the ba-
sis of established noncoronary benefits
and risks, possible coronary benefits and
risks, and patient preference.
Results from WHI indicate that the
combined postmenopausal hormones
CEE, 0.625 mg/d, plus MPA, 2.5 mg/d,
should not be initiated or continued for
the primary prevention of CHD. In ad-
dition, the substantial risks for cardio-
vascular disease and breast cancer must
be weighed against the benefit for frac-
ture in selecting from the available
agents to prevent osteoporosis.
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